Daranide, a 1958 drug, used to be free – now it costs your insurer at least $109,500/yearOn December 21, 2017 by Kenna
Daranide is a drug that was approved for treating glaucoma in 1958; the public domain drug’s manufacture has shifted around for decades, sending its price soaring and plummeting from $0.50/dose to $1365, down to free, and now to $109,500, courtesy of Strongbridge Biopharma, new owners of Taro Pharmaceutical Industries, who started making the drug after Merck discontinued its production.
An investor presentation from Strongbridge Biopharma prices a year’s supply of Daranide (now called Keveyis) at $109,500 to $219,000, with the expectation that the brunt of this will be borne by US health insurers, including Medicaid and Medicare, which are prohibited by law from bargaining for lower drug prices from pharmaceutical companies. The company often gives it away free to uninsured people, to minimize the risk of popular demand for lower prices.
The major use for this drug today is to treat “periodic paralysis” which is just as bad as it sounds.
For patients, this is a double-edged sword. The company is selling the drug in the United States — a big improvement over the years when it wasn’t available at all or had to be imported. And like nearly every drug company with a high-priced treatment, it offers patients support in navigating their insurance or help in paying for the drug.
Anderson, for example, pays nothing. Anderson said Keveyis is not on his insurer’s list of covered drugs, but he gets it free without a co-pay. Providing help to patients in affording drugs by paying co-pays, helping overcome insurance barriers and even giving it away free of charge helps individual patients, and it insulates the drug company from criticism of its price.
This old drug was free. Now it’s $109,500 a year [Carolyn Y. Johnson/LA Times]
(via Naked Capitalism)
In a speech last week, US National Space Council executive director Scott Pace rejected the idea that space was a “global commons” or “the common heritage of mankind” and vowed to make the USA “the most attractive jurisdiction in the world for private-sector investment and innovation in outer space.”
In Labor Market Concentration, a new working paper from economists at U Penn, U Navarra and the Roosevelt Institute, researchers analyze a large US government data-set to determine how many workers live in markets where there is effective only one or two employers, a situation called “monoposony” (when a single buyer has a monopoly).
Why do billionaires like Elon Musk make terrified pronouncements about the imminent rise of self-aware, murderous AIs that use us to reproduce themselves, controlling us instead of serving us?
Humans have been sporting belts since the Bronze Age and not much has changed concerning their functionality. Sure, there have been minor improvements, like reversible designs or buckles that double as bottle openers, but no major breakthroughs have been made in terms of fit. That is, until now. Boasting a unique, hole-free construction, Men’s Trakline […]
Perhaps 2017 wasn’t your most productive year, but that’s okay because the Tim Ferriss Tribe of Mentors Dream Setup Giveaway gives you a chance to make 2018 a year of successful resolutions backed by a trove of productivity-boosting tools. 100 percent free to enter, this giveaway grants you the chance to take home a host […]
There are few (if any) turn-based strategy franchises as prolific and decorated as Sid Meier’s Civilization, and its latest installment is an even greater step forward for the series. Boasting a new city planning system, Civilization VI offers a groundbreaking level of customization that, when combined with reworked combat and building mechanics, makes for a memorable […]